Reuters logo
6 months ago
BRIEF-Morphosys: new data from two phase 3 studies of guselkumab in plaque psoriasis
March 3, 2017 / 1:37 PM / 6 months ago

BRIEF-Morphosys: new data from two phase 3 studies of guselkumab in plaque psoriasis

March 3 (Reuters) - Morphosys AG:

* Announces that its licensee janssen has reported new data from two phase 3 studies of guselkumab in plaque psoriasis

* Both studies met all primary endpoints, according to abstracts submitted by Janssen to AAD 2017 meeting Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below